Document Type : Research Paper

Authors

Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq

Abstract

Background: Antibiotics with β-Lactam rings (β-Lactams), since they were discovered, have enhanced the typical treatment for bacterial infections. Though their resistance can quickly spread on a universal scale, bacterial resistance is primarily caused by the production of β-lactamases. Hence, there is a serious demand to design and create new anti-β-lactamases or inhibitors. Nowadays, the use of β-lactamase inhibitors with β-lactams reduces this resistance. Aim and Methods: This work aimed to help in silico design and dock two new series of 7-aminocephalosporinic acid derivatives (Schiff’s bases and amides) against both the TEM-1 and the IMP-1 β-lactamases. Results: The results revolve around the possible enhanced activity of eight amides and six Schiff base compounds compared with the standard inhibitors (clavulanic acid, sulbactam, and avabactam). These compounds show promising docking interactions with an active pocket site in both enzymes. Conclosin: We can conclude that both the halogenated and the hydrophobic substituents, alone or when containing oxygen atoms, will potentiate the affinity and the binding ability of any compounds when they are added to their structures to act as β-lactamase inhibitors.

Keywords

Main Subjects

  1. Singh GS and Sudheesh S. β-Lactams in natural lactones and lactams: synthesis, occur­rence and biological activity; Janecki, T., Ed.; Wiley-VCH, 2014:101–145.
  2. Halat DH and Moubareck CA. The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria.  Antibiotics, 2020;9:186.
  3. Jubeh B, Breijyeh Z and Karaman R. Antibacterial Prodrugs to Overcome Bacterial Resistance. Molecules, 2020;25:1543.
  4. Monaco M, Giani T, Raffone M, Arena F, Garcia FA, Pollini S, Grundmann H, Pantosti A, Rossolini GM. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro surveillance, 2014;19(42):20939.
  5. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr. Opin. Pharmacol, 2014;18:56-60.
  6. Adesoji AT, Onuh JP and Okunye OL. Bacteria resistance to cephalosporins and its implication to public health. Journal of Bacteriology and Mycology, 2016;3(1):1021.
  7. Elshamy AA and Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci. OA, 2020;6(3),FSO438.
  8. Bush K. Past and present perspectives on betalactamases. Antimicrob. Agents Chemother. 2018; 62(10):18.
  9. Ferri M, Ranucci E, Romagnoli P and Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. Crit. Rev. Food Sci. Nutr., 2017;57:2857–2876.
  10. Reddy N, Shungube M, Arvidsson PI, Baijnath S, Kruger HG, et al. A 2018-2019 patent review of metallo beta-lactamase inhibitors, Expert Opinion on Therapeutic Patents, 2020;30(7). https://doi.org/10.1080/13543776.2020.1767070.
  11. Bonomo RA. b-Lactamases: A focus on current challenges. Cold Spring Harb. Perspect. Med., 2017; 7(1):a025239.
  12. Drawz SM and Bonomo RA. Three decades of b-lactamase inhibitors. american society for microbiology, Clinical Microbiology Reviews, 2010;23(7):160-201.
  13. Olugbenga OO. Bacterial Resistance; A Perspective on Beta-Lactamase Enzymes. EC Microbiology, 2020;16(3):1-12.
  14. King AM. Discovery and characterization of novel beta-lactamase inhibitors. Ph.D. Thesis, McMaster University, Chemistry and Chemical Biology, 2016.
  15. Mahmood AAJ, Al-Iraqi MA and Al-Abacchi FT. Design, synthesis and anti-β-lactamase activity for new monobactam compounds. Materials Today: Proceedings, 2021;42:1860-1866 .
  16. Gawehn E, Hiss JA and Schneider G. Deep learning in drug discovery. Mol. Inform., 2016;35:3-14.
  17. Shah B, Modi P & Sagar SR. In Silico Studies On Therapeutic Agents For Covid-19: Drug Repurposing Approach. Life Sciences, 2020;252:117652.
  18. Mahmood AAJ, Al-Iraqi MA and Abachi FT. Design, synthesis, and evaluation the anti-β-lactamase activity of new sulphathiazole-derived monobactam compounds. Iraqi Journal of Pharmacy, 2020,17(1):19-36
  19. Mahmood AAJ, Al-Iraqi MA and Abachi FT. New 4,4′-methylenedianiline monobactame compounds: Synthesis, antioxidant and antimicrobial activities evaluation, AIP Conference Proceedings, 2022;2660: 020024. 
  20. Gawehn E, Hiss JA and Schneider G. Deep learning in drug discovery. Mol. Inform., 2016,35:1-12.
  21. Abdul Hameed A, al-Rashida M, Uroos M, Ali SA and Khan KM. Schiff bases in medicinal chemistry: a patent review (2010-2015), Expert Opin Ther Pat, 2017, 27(1):63-79.
  22. Mahmood AAJ. Green synthesis of Schiff bases: a review study. Iraqi Journal of Pharmacy, 2022,18(2):180-193.
  23. Dunetz JR, Magano J and Weisenburger GA. Large-scale applications of amide coupling reagents for the synthesis of pharmaceuticals. Org. Process Res. Dev., 2016;20:140-177.
  24. Bousfield TW, Pearce KPR and Nyamini SB. Synthesis of amides from acid chlorides and amines in the bio-based solvent Cyrene. The Royal Society of Chemistry; Green Chem., 2019; 21:3675-3681
  25. Lin X, Li X and Lin X. A review on applications of computational methods in drug screening and design. Molecules, 2020;25:1375.
  26. Mahmood AAJ, Al-Iraqi MA and Abachi FT. Fluorine important element in new drugs synthesis: Review Study. Iraqi Journal of Pharmacy, 2018;15(1):37-45.